We randomly assigned 257 premenopausal women with
operable hormone-receptor–negative breast cancer to receive standard
chemotherapy with the GnRH agonist goserelin (goserelin group) or standard
chemotherapy without goserelin (chemotherapy-alone group). The primary study
end point was the rate of ovarian failure at 2 years, with ovarian failure
defined as the absence of menses in the preceding 6 months and levels of
follicle-stimulating hormone (FSH) in the postmenopausal range. Rates were
compared with the use of conditional logistic regression. Secondary end points
included pregnancy outcomes and disease-free and overall survival.
No comments:
Post a Comment